P. pastoris expressional vector harbouring the promoter. E. coli-P. pastoris shuttle vector, .
Invitrogen
pPPE3
pBGP1 derivative in which the three BspHI restriction sites are deleted including one situated in the promoter by using site-directed mutagenesis with primer pair 1, 2, and 3, , .
This study
pPPE8
pPPE3 derivative in which a BspHI restriction enzyme site was inserted in the start of the zeocin-resistance gene by using site-directed mutagenesis with primer pair 4, .
This study
pPPE10
pPPE8 derivative in which the zeocin-resistance gene was substituted with the kanamycin-resistance gene from plasmid pIB11. The gene was amplified from pIB11 with primer pair 5 and end digested with BspHI and EcoRV prior to ligation into the corresponding sites of pPPE8, , , .
This study
pPPE11
pPPE10 derivative in which a NcoI restriction enzyme site was inserted in the start of the Alpha signal by using site-directed mutagenesis with primer pair 6, , , .
This study
pPPE12
pPPE11 derivative in which the zeocin-resistance gene was inserted as reporter for the modified promoter. The zeocin-resistance gene was amplified from plasmid pBGP1 with primer pair 7 and end digested with NcoI and NotI prior to ligation into the corresponding sites of pPPE11, , , .
This study
pPPE17
pPPE12 derivative in which the modified promoter was substituted with the . The promoter was amplified from pPICZ A with primer pair 8 and end digested with SpeI and NcoI prior to ligation into the corresponding sites of pPPE12, , , .
This study
pIPA1
pPICZ A derivative in which the BspHI restriction enzyme site in the promoter is deleted by using site directed mutagenesis with primer pair 9, .
This study
pIPA4
pIPA1 derivative in which an EcoRI restriction enzyme site is inserted directly upstream of the putative TATA-box in the promoter by using site-directed mutagenesis with primer pair 10, .
This study
pIPA5
pIPA4 derivative in which a NheI restriction enzyme site is inserted downstream of the transcriptional start site in the promoter by using site-directed mutagenesis with primer pair 11, .
This study
pPPE20
Similar to pPPE17 except for that the promoter was substituted with the modified promoter from plasmid pIPA5. The promoter was amplified from plasmid pIPA5 with primer pair 12 and end digested with SpeI and NcoI prior to ligation into the corresponding sites of pPPE12, , , .
This study
pPPE22
Similar to pPPE17 except for that the promoter was substituted with the wild-type promoter from plasmid pBGP1 by subcloning the SpeI/MfeI fragment from plasmid pBGP1 into the corresponding sites of plasmid pPPE12, , , .
This study
pPPE35
Similar to pPPE17 except for that the gene is substituted with the luc+ gene (encoding firefly luciferase). The luc+ gene was amplified from plasmid pGL3-control vector with primer pair 13 and end digested with NcoI and NotI prior to ligation into the corresponding sites of pPPE17, , , .
This study
pPPE50
Similar to pPPE20 except for that a KpnI restriction enzyme site is inserted in the promoter about 90 base pairs upstream of the EcoRI restriction enzyme site by using site-directed mutagenesis with primer pair 14, , , .
This study
aAp: ampicillin; Km: kanamycin; Zc: Zeocin, G418: aminoglycoside antibiotic.
bSequences of the primer pairs are listed in Table 2.
cThe target region was subcloned and verified by sequencing for all of the site-directed mutagenesis applications. Also, all cloned regions amplified by PCR were verified by sequencing.